USD 169.5
(-0.56%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 3.68 Billion USD | 17.18% |
2022 | 3.35 Billion USD | 4.18% |
2021 | 3.17 Billion USD | 6.85% |
2020 | 2.68 Billion USD | 22.38% |
2019 | 2.45 Billion USD | 7.16% |
2018 | 2.21 Billion USD | 14.97% |
2017 | 1.94 Billion USD | 21.97% |
2016 | 1.63 Billion USD | 41.33% |
2015 | 868 Million USD | 2.74% |
2014 | 1.14 Billion USD | 14.96% |
2013 | 1.01 Billion USD | -16.29% |
2012 | 941 Million USD | 23.78% |
2011 | 635 Million USD | 72.29% |
2010 | 400 Million USD | 44.35% |
2009 | 2 Million USD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 1.03 Billion USD | 11.43% |
2024 Q1 | 927 Million USD | 11.02% |
2024 Q3 | 955 Million USD | 2.23% |
2023 Q2 | 975 Million USD | 19.19% |
2023 FY | - USD | 17.18% |
2023 Q1 | 818 Million USD | 18.38% |
2023 Q3 | 830 Million USD | -14.87% |
2023 Q4 | 835 Million USD | 0.6% |
2022 Q1 | 907 Million USD | 50.17% |
2022 FY | - USD | 4.18% |
2022 Q4 | 691 Million USD | -18.99% |
2022 Q3 | 853 Million USD | -0.23% |
2022 Q2 | 855 Million USD | -5.73% |
2021 Q4 | 604 Million USD | -28.52% |
2021 Q2 | 838 Million USD | -3.12% |
2021 FY | - USD | 6.85% |
2021 Q3 | 845 Million USD | 0.84% |
2021 Q1 | 865 Million USD | 38.62% |
2020 Q4 | 624 Million USD | -19.69% |
2020 FY | - USD | 22.38% |
2020 Q1 | 657 Million USD | 19.24% |
2020 Q2 | 671 Million USD | 2.13% |
2020 Q3 | 777 Million USD | 15.8% |
2019 Q1 | 540 Million USD | 1.89% |
2019 Q4 | 551 Million USD | -19.44% |
2019 FY | - USD | 7.16% |
2019 Q3 | 684 Million USD | 7.38% |
2019 Q2 | 637 Million USD | 17.96% |
2018 Q2 | 560 Million USD | 14.52% |
2018 Q1 | 489 Million USD | -5.05% |
2018 FY | - USD | 14.97% |
2018 Q4 | 530 Million USD | -13.68% |
2018 Q3 | 614 Million USD | 9.64% |
2017 Q3 | 533 Million USD | 18.18% |
2017 Q1 | 441 Million USD | 40.89% |
2017 FY | - USD | 21.97% |
2017 Q4 | 515 Million USD | -3.38% |
2017 Q2 | 451 Million USD | 2.27% |
2016 Q3 | 399 Million USD | 6.68% |
2016 FY | - USD | 41.33% |
2016 Q1 | 398 Million USD | 144.17% |
2016 Q2 | 374 Million USD | -6.03% |
2016 Q4 | 313 Million USD | -21.55% |
2015 FY | - USD | 2.74% |
2015 Q4 | 163 Million USD | -50.61% |
2015 Q3 | 330 Million USD | 16.61% |
2015 Q2 | 283 Million USD | 3.28% |
2015 Q1 | 274 Million USD | 28.04% |
2014 FY | - USD | 14.96% |
2014 Q4 | 214 Million USD | -24.91% |
2014 Q3 | 285 Million USD | 14.46% |
2014 Q1 | 274 Million USD | 32.37% |
2014 Q2 | 249 Million USD | -9.12% |
2013 Q1 | 236 Million USD | 14.56% |
2013 Q2 | 214 Million USD | -9.32% |
2013 Q3 | 232 Million USD | 8.41% |
2013 Q4 | 207 Million USD | -10.78% |
2013 FY | - USD | -16.29% |
2012 Q4 | 206 Million USD | -26.69% |
2012 Q3 | 281 Million USD | -13.54% |
2012 FY | - USD | 23.78% |
2012 Q2 | 325 Million USD | 32.11% |
2012 Q1 | 246 Million USD | 23.62% |
2011 FY | - USD | 72.29% |
2011 Q1 | 199 Million USD | 0.0% |
2011 Q2 | 187 Million USD | -6.03% |
2011 Q3 | 273 Million USD | 45.99% |
2011 Q4 | 199 Million USD | -27.11% |
2010 FY | - USD | 44.35% |
2009 FY | - USD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Editas Medicine, Inc. | -163.11 Million USD | 2359.115% |
Dynavax Technologies Corporation | 9.66 Million USD | -38023.319% |
Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -3650.178% |
Perrigo Company plc | 646.2 Million USD | -470.257% |
Illumina, Inc. | -608 Million USD | 706.086% |
Thermo Fisher Scientific Inc. | 10.8 Billion USD | 65.88% |
Iovance Biotherapeutics, Inc. | -449.01 Million USD | 920.689% |
Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 132.674% |
IQVIA Holdings Inc. | 3.25 Billion USD | -13.176% |
Heron Therapeutics, Inc. | -103.79 Million USD | 3650.37% |
Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 20.824% |
Unity Biotechnology, Inc. | -37.28 Million USD | 9983.861% |
Waters Corporation | 1.02 Billion USD | -260.479% |
Biogen Inc. | 2.37 Billion USD | -55.027% |
Sangamo Therapeutics, Inc. | -87.42 Million USD | 4314.945% |
Evolus, Inc. | -41.81 Million USD | 8913.681% |
Adicet Bio, Inc. | -136.53 Million USD | 2798.942% |
Cara Therapeutics, Inc. | -117.65 Million USD | 3232.172% |
bluebird bio, Inc. | -167.16 Million USD | 2304.462% |
Esperion Therapeutics, Inc. | -150.1 Million USD | 2554.899% |
FibroGen, Inc. | -261.4 Million USD | 1509.69% |
Agilent Technologies, Inc. | 1.67 Billion USD | -119.738% |
Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 8392.695% |
Homology Medicines, Inc. | -47.75 Million USD | 7816.308% |
Geron Corporation | -174.78 Million USD | 2208.341% |
Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 1715.371% |
Amicus Therapeutics, Inc. | -92.07 Million USD | 4101.998% |
Myriad Genetics, Inc. | -67.8 Million USD | 5535.103% |
Viking Therapeutics, Inc. | -100.82 Million USD | 3754.775% |
Intellia Therapeutics, Inc. | -506.31 Million USD | 827.808% |
Abeona Therapeutics Inc. | -50.57 Million USD | 7386.641% |
Mettler-Toledo International Inc. | 1.16 Billion USD | -216.568% |
BioMarin Pharmaceutical Inc. | 310.28 Million USD | -1087.622% |
Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 19.982% |
Kala Pharmaceuticals, Inc. | -36.08 Million USD | 10312.849% |
Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 1702.104% |
Atara Biotherapeutics, Inc. | -265.99 Million USD | 1485.354% |
Verastem, Inc. | -83.16 Million USD | 4530.897% |
Nektar Therapeutics | -243.1 Million USD | 1615.793% |
Axsome Therapeutics, Inc. | -224.99 Million USD | 1737.843% |
Aclaris Therapeutics, Inc. | -87.98 Million USD | 4288.214% |
Sarepta Therapeutics, Inc. | -439.19 Million USD | 939.033% |
OPKO Health, Inc. | -65.51 Million USD | 5724.58% |
Exelixis, Inc. | 196.6 Million USD | -1774.345% |
Neurocrine Biosciences, Inc. | 416.1 Million USD | -785.604% |
Corcept Therapeutics Incorporated | 108.32 Million USD | -3301.832% |
Anavex Life Sciences Corp. | -55.75 Million USD | 6709.154% |
uniQure N.V. | -253.1 Million USD | 1555.946% |
Imunon, Inc. | -20.78 Million USD | 17831.456% |
Blueprint Medicines Corporation | -474.61 Million USD | 876.424% |
Insmed Incorporated | -654.73 Million USD | 662.82% |
Halozyme Therapeutics, Inc. | 451.94 Million USD | -715.361% |
Agios Pharmaceuticals, Inc. | -345.46 Million USD | 1166.678% |
TG Therapeutics, Inc. | 26.1 Million USD | -14018.774% |
Incyte Corporation | 919.42 Million USD | -300.794% |
Emergent BioSolutions Inc. | -505.29 Million USD | 829.27% |